| Literature DB >> 27135886 |
Sulaiman S Ibrahim1, Miranda Ndula1, Jacob M Riveron1, Helen Irving1, Charles S Wondji1.
Abstract
Carbamates are increasingly used for vector control notably in areas with pyrethroid resistance. However, a cross-resistance between these insecticides in major malaria vectors such as Anopheles funestus could severely limit available resistance management options. Unfortunately, the molecular basis of such cross-resistance remains uncharacterized in An. funestus, preventing effective resistance management. Here, using a genomewide transcription profiling, we revealed that metabolic resistance through upregulation of cytochrome P450 genes is driving carbamate resistance. The P450s CYP6P9a, CYP6P9b and CYP6Z1 were the most upregulated detoxification genes in the multiple resistant mosquitoes. However, in silico docking simulations predicted CYP6Z1 to metabolize both pyrethroids and carbamates, whereas CYP6P9a and CYP6P9b were predicted to metabolize only the pyrethroids. Using recombinant enzyme metabolism and inhibition assays, we demonstrated that CYP6Z1 metabolizes bendiocarb and pyrethroids, whereas CYP6P9a and CYP6P9b metabolize only the pyrethroids. Other upregulated gene families in resistant mosquitoes included several cuticular protein genes suggesting a possible reduced penetration resistance mechanism. Investigation of the target-site resistance in acetylcholinesterase 1 (ace-1) gene detected and established the association between the new N485I mutation and bendiocarb resistance (odds ratio 7.3; P < 0.0001). The detection of multiple haplotypes in single mosquitoes after cloning suggested the duplication of ace-1. A TaqMan genotyping of the N485I in nine countries revealed that the mutation is located only in southern Africa with frequency of 10-15% suggesting its recent occurrence. These findings will help in monitoring the spread and evolution of carbamate resistance and improve the design of effective resistance management strategies to control this malaria vector.Entities:
Keywords: Anopheles funestus; CYP6Z1; acetylcholinesterase 1; carbamates; cross-resistance; malaria; pyrethroids
Mesh:
Substances:
Year: 2016 PMID: 27135886 PMCID: PMC4950264 DOI: 10.1111/mec.13673
Source DB: PubMed Journal: Mol Ecol ISSN: 0962-1083 Impact factor: 6.185
Probes from detoxification genes and genes associated with bendiocarb resistance. Probes upregulated in R‐C comparison with P < 0.01 and fold change >2 using 4 × 44k chip. Significant expression in other comparisons for bendiocarb and for permethrin is also indicated
| Gene name |
|
|
| C‐S |
|
| Description |
|---|---|---|---|---|---|---|---|
| CYP6P9a | 5.2 | 0.0026 | 12.6 | 5.6 | 7.9 | 23.2 | Cytochrome p450 |
| CYP6P9a | 2.4 | 0.0067 | 17.3 | 7.8 | 3.4 | 37.1 | Cytochrome p450 |
| CD577515.1 | 3.1 | 0.0066 | 4.2 | 3.9 | Cuticle protein | ||
| CYP6Z1 | 7.3 | 0.0014 | 2.9 | 7.8 | 2.9 | Cytochrome p450 | |
| EE589616.1 | 20.0 | 0.0021 | 4.7 | 38.2 | 9.6 | d7‐related 1 protein | |
| EE589737.1 | 15.5 | 0.0019 | 4.9 | 31.8 | d7‐related 1 protein | ||
| CYP6Z1 | 5.0 | 0.0023 | 2.5 | −2.6 | 6.1 | 3.1 | Cytochrome p450 |
| EE589504.1 | 16.0 | 0.0008 | 4.6 | −9.9 | 28.4 | 6.9 | d7‐related 1 protein |
| BU038886 | 5.9 | 0.0039 | 2.5 | −3.3 | 10.3 | 3.8 | Trypsin |
| EE589855.1 | 16.7 | 0.0010 | 4.3 | −12.1 | 26.1 | d7‐related 1 protein | |
| AGAP008292‐RA | 6.5 | 0.0024 | 2.7 | −2.9 | 4.3 | Trypsin | |
| CD578260.1 | 5.6 | 0.0014 | 2.4 | −3.7 | 3.5 | Trypsin | |
| combined_c6791 (CYP9J11) | 6.8 | 0.0013 | 10.8 | 9.3 | Cytochrome p450 | ||
| CYP6Z1 | 6.7 | 0.0021 | 2.7 | 2.7 | Cytochrome p450 | ||
| Combined_c6791 (CYP9J11) | 5.3 | 0.0010 | 10.8 | 8.6 | Cytochrome p450 | ||
| CYP6P9b | 3.1 | 0.0054 | 4.2 | 5.4 | Cytochrome p450 | ||
| CYP6P9b | 2.4 | 0.0058 | 3.9 | 4.8 | Cytochrome p450 | ||
| Pseudo_P450_between_6AA2_and_6P9a | 3.0 | 0.0030 | 2.4 | Cytochrome p450 | |||
| CYP6P4a | 2.1 | 0.0032 | 3.1 | Cytochrome p450 | |||
| CYP6P5 | 2.1 | 0.0065 | 3.5 | Cytochrome p450 | |||
| Combined_c4812 | 2.8 | 0.0062 | 3.9 | Short‐chain dehydrogenase | |||
| CD577519.1 | 3.0 | 0.0039 | 3.3 | Cuticle protein | |||
| CD577517.1 | 2.9 | 0.0039 | 3.0 | Cuticle protein | |||
| CD577317.1 | 2.8 | 0.0023 | 2.8 | Cuticle protein | |||
| CD577518.1 | 2.6 | 0.0027 | 2.6 | Cuticle protein | |||
| CD577694.1 | 2.5 | 0.0030 | 2.9 | Cuticle protein | |||
| CD664220.1 | 2.5 | 0.0014 | 3.5 | Cuticle protein | |||
| CD577516.1 | 2.3 | 0.0060 | 3.3 | Cuticle protein | |||
| CD577316.1 | 2.2 | 0.0044 | 2.8 | Cuticle protein | |||
| EE589911.1 | 10.3 | 0.0014 | 11.4 | GE‐rich salivary gland protein | |||
| CD578169.1 | 8.7 | 0.0022 | 12.7 | Trypsin | |||
| Combined_c8512 | 5.7 | 0.0035 | 4.1 | Serine protease 14 | |||
| Combined_c4956 (CYP4G16) | 9.1 | 0.0022 | −9.5 | 9.6 | Cytochrome p450 | ||
| Combined_c4956 (CYP4G16) | 8.7 | 0.0016 | −9.1 | 10.1 | Cytochrome p450 |
Figure 1Transcriptional profiling of bendiocarb and permethrin resistance. (A) qRT–PCR differential expression of nine genes (upregulated in microarray) between the susceptible FANG and bendiocarb‐resistant (R‐S bendiocarb), permethrin‐resistant (R‐S permethrin) and control mosquitoes (C‐S). (B) Correlation between microarray data and qRT–PCR data of genes selected from the list of upregulated probes.
Figure 2Functional validation of the role of candidate cytochrome P450 genes in carbamate/pyrethroid cross‐resistance. (A) Percentage depletion of 20 μM carbamate and pyrethroid insecticides with Anopheles funestus CYP450s. Results are an average of three replicates (n = 3) compared with negative control. * and ** Significantly different from negative control (‐NADPH) at P < 0.05 BS P < 0.01, respectively. (B) Michaelis–Menten plot and kinetic constants of the CYP6Z1‐mediated metabolism of permethrin and deltamethrin. Results are an average of three replicates (n = 3) compared with negative control; (C) overlay of HPLC chromatogram of the CYP6Z1 metabolism of bendiocarb with –NADPH in red and +NADPH in blue. Bendiocarb peaks are designated B1 and B2 and putative metabolites peaks from +NADPH samples designated M1‐M7 (4.396–7.75 min) and M8 (18.026 min). (D) Allosteric sigmoidal curve of CYP6Z1 metabolism of bendiocarb. Results are average of three replicates (n = 3) compared with negative control. Khalf = . h = 1.05.
Figure 3Assessment of biochemical interactions between candidate P450s and different insecticides using fluorescent probes. (A) Testing of O‐dealkylation activities of CYP6P9a, CYP6P9b and CYP6Z1 using fluorescent probes. The solid bars indicate average of significant turnovers of three experimental replicates compared to negative controls (‐NADPH). (B) Inhibition assays: Mean IC 50 values of the test insecticide inhibitors against CYP450‐mediated dealkylation of DEF. Data represent mean IC 50 at eight concentrations of each insecticide plus or minus standard deviation. Error bars represent the variation in the values of the IC 50 between different concentrations.
Figure 4Comparative in silico docking of bendiocarb to P450 models. (A) Bendiocarb in the active site of CYP6P9b. Bendiocarb is in stick format and yellow, while CYP6P9b is presented as helices and cyan. Haem atoms are in stick format and grey. Distance between possible sites of metabolism and haem iron is annotated in Angstrom. (B) Conformation of bendiocarb in the active site of CYP6Z1. CYP6Z1 is presented in green helices.
Figure 5N485I association with bendiocarb resistance across Africa. (A) Evidence of correlation between N485I genotypes and bendiocarb resistance with phenotypes form 60‐min exposure to 0.1% bendiocarb. (B) Evidence of stronger correlation between N485I genotypes and bendiocarb resistance with phenotypes form 45‐min exposure to 0.1% bendiocarb. (C) The N485I geographical distribution across Africa showing a correlation with the bendiocarb resistance distribution in southern Africa. (D) 3D folding of the two generated models of Anopheles funestus ace‐1 for the wild and mutated alleles at N485I with the template 2C58 revealing a conservative folding. It also reveals that the Asn485Ile mutation maps to an external loop considerable distance away from the catalytic hotspot.